An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer

類似資料

• Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
  著者:: Davies, Kurtis D., 等
  出版事項: (2017)
• Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples
  著者:: Davies, Kurtis D., 等
  出版事項: (2018)
• The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
  著者:: Patil, Tejas, 等
  出版事項: (2018)
• Diagnostic Assays for Identification of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
  著者:: Weickhardt, Andrew J., 等
  出版事項: (2012)
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
  著者:: Doebele, Robert C., 等
  出版事項: (2012)